KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources

A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc , a medical diagnostics company that develops tests to identify tuberculosis, with a $400 million acquisition offer, people familiar with the matter said on Thursday.